Novartis Bets Big On Next-Gen Gene Therapy With Voyager Pact
Pays $54m Upfront To Access Capsids For Brain Diseases
Executive Summary
The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.
You may also be interested in...
Sandrock Joins Voyager As CEO To Advance New Gene Therapy Technology Into The Clinic
The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.
Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: big pharma and Ukraine; new gene therapy deal for Novartis; Phase III hemophilia success for Sanofi; J&J’s Gorsky’s views on Asia innovation; and a look at pharma’s deal-making activity last year.